Emerald Health Therapeutics, Inc.
EMHTF · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.00 | -0.00 | -0.00 |
| FCF Yield | -161.18% | -123.79% | -553.54% | -538.05% |
| EV / EBITDA | 0.10 | 0.32 | -0.32 | 0.92 |
| Quality | ||||
| ROIC | -104.89% | -49.77% | -86.56% | -17.52% |
| Gross Margin | -66.72% | -82.37% | -71.21% | -159.09% |
| Cash Conversion Ratio | 0.44 | 0.24 | 0.22 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | -21.90% | 81.98% | 178.80% | 97.38% |
| Free Cash Flow Growth | -29.03% | 71.29% | -2.33% | -374.25% |
| Safety | ||||
| Net Debt / EBITDA | 0.42 | 0.66 | -0.24 | 1.25 |
| Interest Coverage | -54.95 | -7.60 | -146.60 | -138.98 |
| Efficiency | ||||
| Inventory Turnover | 19.01 | 3.84 | 3.24 | 0.64 |
| Cash Conversion Cycle | 0.84 | 601.46 | 36.15 | 3,348.08 |